Scientists develop risk score to forecast bronchiectasis attacks
NCT ID NCT07599839
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is creating a new scoring system called BASE to measure how severe bronchiectasis is and predict the chance of a flare-up over the next year. Researchers will follow 750 adults with non-cystic fibrosis bronchiectasis for 12 months, collecting routine medical data. No new treatments are being tested; the goal is to give doctors a better way to identify high-risk patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple, objective tool for doctors to better predict which patients are at risk of worsening and tailor monitoring or treatment.
- What could go wrong
- This is an observational study, not a treatment trial. The tool may not prove accurate enough in practice, and results may not apply to all patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 750 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with non-cystic fibrosis bronchiectasis (NCFB) attending outpatient clinics, inpatient wards, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period will be prospectively screened for eligibility. Eligible participants will have clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB) and will undergo baseline assessment using the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework, followed by 12-month follow-up for bronchiectasis exacerbations, hospitalization, functional change, inflammatory marker change, and clinical outcomes. Participants will receive routine clinical care, and no treatment or intervention will be assigned by the study protocol.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients aged 18 years or older. * Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT). * Clinically stable or routinely assessed patients with non-cystic fibrosis bronchiectasis (NCFB) eligible for baseline severity and risk assessment. * Patients attending outpatient clinic, inpatient ward, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period. * Patients suitable for prospective baseline assessment using the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework. * Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol. * Ability to complete planned 12-month follow-up for bronchiectasis exacerbation and outcome assessment. * Written informed consent obtained from the patient or legal representative. Exclusion Criteria: * Cystic fibrosis-related bronchiectasis. * Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis. * Active pulmonary tuberculosis at enrollment. * Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment. * Active malignancy or terminal non-respiratory illness expected to prevent 12-month follow-up. * Acute life-threatening illness preventing safe enrollment or baseline assessment. * Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment. * Inability to complete the required baseline or Bronchiectasis Assessment of Severity and Exacerbations (BASE) assessment according to the study protocol. * Inability or unwillingness to complete planned 12-month follow-up. * Refusal to participate.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bronchiectasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Assiut university-Faculty of Medicine
RECRUITINGAsyut, Asyut Egypt, 71515, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Antibiotic flush directly into the lungs tested against bronchiectasis Flare-Ups
- Can a simpler antibiotic course clear lung infections as well as a stronger one?
- A new twist on lung rehab: helping the helpers
- Could a Pulsed-Air device revolutionize mucus clearance for bronchiectasis?
- Gum treatment may lower lung flare-ups in bronchiectasis patients
- Can a daily pill cut dangerous lung Flare-Ups in bronchiectasis?